Samsung enters agreement on manufacture of antibody cancer drug

Published: 19-Sep-2023
Manufacturing

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance

Samsung Biologics has announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. 

Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company’s latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea. 

This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply

- John Rim, President and CEO of Samsung Biologics

“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” said John Rim, President and CEO of Samsung Biologics. 

“This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity,” continued Rim. 

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering development and manufacturing solutions from cell line development to final aseptic fill/finish.

  • Companies:
  • Samsung Biologics
See more

You may also like

Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

Read more
From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing

Trending Articles

  1. Optimising RNA production for faster and cheaper pharmaceutical manufacturing RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the avoidance of scaling issues
  2. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
  3. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  4. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  5. Enhancing sterility: the crucial role of isolators in sterile fill-finish Maintaining the highest levels of sterility is paramount to ensure the safety and efficacy of drugs, with good aseptic manufacturing practices playing a pivotal role in safeguarding patient health and well-being

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Unearthing the potential of CDMO services to accelerate complex biologics development

The biologics landscape continues to transform in response to technological advancements and a growing understanding of molecular biology and biochemistry. As a result, an influx of both novel and complex therapeutics is entering the development pipeline, including bispecific antibodies (BsAbs), fusion proteins and antibody-drug conjugates (ADCs). However, these new moieties bring unique and potentially unfamiliar development and manufacturing difficulties
Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Manufacturing

Samsung Biologics commences construction on fifth plant

The company will invest over KRW 1.9 trillion in the new facility and break ground in the first half of this year
Manufacturing

Bioprocessing in the balance: part I

Dr Kevin Robinson recently caught up with Na Hye-jung, Head of Global Regulatory Affairs at Samsung Biologics, to pose the question: how do you solve the process optimisation equation of speed-to-market and cost efficiencies while maintaining a safe environment for both operators and end users?
Manufacturing

Bringing performance, quality and safety to the pharmaceutical industry

Catching up with a trio of industry outsourcing experts, Dr Kevin Robinson explores the key trends have had the biggest impact on the pharmaceutical’s contract service industry in recent times
Manufacturing

GreenLight and Samsung complete first commercial-scale engineering run for mRNA COVID-19 vaccine

GreenLight and Samsung Biologics have announced that the mRNA synthesis reaction was achieved without the need for customisation, using standard equipment for contract development and manufacturing companies (CDMOs)
Subscribe now